Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

AJAY S GUPTA

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1487651873
CMS profile
203691
Location
FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$110,309.79

288 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 5 of 6; records 201–250 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

AJAY S GUPTA

NPI 1487651873 · CMS profile ID 203691

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

FORT WAYNE, IN

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 5 of 6; records 201–250 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1487651873?year=2019&recipient=provider&page=5#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
AJAY S GUPTA, NPI 1487651873, CMS profile ID 203691. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1487651873?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). AJAY S GUPTA, NPI 1487651873, CMS profile ID 203691. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 5 of 6; records 201–250 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1487651873?year=2019&recipient=provider&page=5#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
AJAY S GUPTA, NPI 1487651873, CMS profile ID 203691, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 5 of 6; records 201–250 of 288 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1487651873?year=2019&recipient=provider&page=5#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

288 matching records · $110,309.79 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 288 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 201–250 of 288.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
EMD Serono, Inc. $14.3204/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702993517 CMS
CSL Behring $20.0204/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 683880157 CMS
EMD Serono, Inc. $89.0904/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702956519 CMS
Mallinckrodt Enterprises LLC $15.1004/09/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704781979 CMS
Alexion Pharmaceuticals, Inc. $20.4204/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695562149 CMS
Celgene Corporation $50.0004/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672753765 CMS
Celgene Corporation $29.9804/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672758603 CMS
Celgene Corporation $29.9904/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672778587 CMS
Celgene Corporation $39.9804/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 673000729 CMS
Celgene Corporation $215.4604/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672753337 CMS
Celgene Corporation $132.9204/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672758531 CMS
Celgene Corporation $308.7004/04/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672771389 CMS
GENZYME CORPORATION $19.4804/03/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693972775 CMS
Lilly USA, LLC $11.5604/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 657651773 CMS
UCB, Inc. $1.3304/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688339959 CMS
UCB, Inc. $1.3204/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688339963 CMS
UCB, Inc. $13.4704/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688340255 CMS
Lundbeck LLC $13.2503/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684301881 CMS
Biogen, Inc. $19.6003/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596411 CMS
EMD Serono, Inc. $8.3303/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703011915 CMS
EMD Serono, Inc. $1.6203/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 703024597 CMS
GENZYME CORPORATION $2,573.0003/20/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693988167 CMS
Zyla Life Sciences $11.6803/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 704844971 CMS
Alexion Pharmaceuticals, Inc. $14.7203/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695562137 CMS
Sunovion Pharmaceuticals Inc. $16.9603/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688079281 CMS
Genentech USA, Inc. $13.3803/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681238489 CMS
Genentech USA, Inc. $4.0103/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681246597 CMS
UCB, Inc. $20.5103/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688266503 CMS
UCB, Inc. $2.3403/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688266659 CMS
Alexion Pharmaceuticals, Inc. $16.5503/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 695562133 CMS
UCB, Inc. $2.8803/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688266385 CMS
Greenwich Biosciences, Inc. $20.7103/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 701789651 CMS
EMD Serono, Inc. $645.0003/07/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702949333 CMS
GENZYME CORPORATION $17.4503/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694001013 CMS
EMD Serono, Inc. $14.6203/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702992075 CMS
Celgene Corporation $29.9303/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 672746405 CMS
Genentech, Inc. $8.9302/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681171061 CMS
Novartis Pharmaceuticals Corporation $24.7802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548923 CMS
Biogen, Inc. $13.5002/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596421 CMS
Allergan Inc. $21.5702/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670469285 CMS
Novartis Pharmaceuticals Corporation $22.4002/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548909 CMS
Novartis Pharmaceuticals Corporation $22.5002/22/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 659548973 CMS
Biogen, Inc. $57.6002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 660596437 CMS
Genentech USA, Inc. $11.4002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681184371 CMS
Sunovion Pharmaceuticals Inc. $14.5302/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 688079279 CMS
Lundbeck LLC $15.7502/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684301879 CMS
EMD Serono, Inc. $2,580.0002/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702946981 CMS
GENZYME CORPORATION $17.7702/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693929751 CMS
Supernus Pharmaceuticals, Inc. $9.4602/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702309061 CMS
GENZYME CORPORATION $438.4102/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 694241397 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $110,309.79 288
PY2020 $47,675.92 161
PY2021 $68,481.86 219
PY2022 $66,301.13 215
PY2023 $27,171.82 186
PY2024 $47,051.73 46
PY2025 $44,272.77 49

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $447,858.64 27
PY2024 Principal investigator $460,375.00 36
PY2023 Principal investigator $466,833.39 47
PY2022 Principal investigator $123,732.30 17
PY2021 Principal investigator $295,438.68 45
PY2020 Principal investigator $166,601.25 28
PY2019 Principal investigator $79,449.70 8

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $20,850.00 12/15/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088688
Principal investigator 1 Genentech, Inc. $90.00 11/05/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571817
Principal investigator 1 Genentech, Inc. $2,913.00 10/23/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571821
Principal investigator 1 GENZYME CORPORATION $780.00 10/20/2025 Non-covered Recipient Entity
Indiana University Health Inc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092257
Principal investigator 1 GENZYME CORPORATION $2,500.00 10/20/2025 Non-covered Recipient Entity
Indiana University Health Inc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092265
Principal investigator 1 Genentech, Inc. $1,000.00 10/17/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571824
Principal investigator 1 Genentech, Inc. $63.85 10/17/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571829
Principal investigator 1 Genentech, Inc. $90.00 09/25/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571813
Principal investigator 1 GENZYME CORPORATION $65.00 09/08/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088610
Principal investigator 1 GENZYME CORPORATION $27,722.00 09/08/2025 Non-covered Recipient Entity
Indiana University Health Inc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092214
Principal investigator 1 GENZYME CORPORATION $110.00 08/25/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088616
Principal investigator 1 Genentech, Inc. $90.00 08/08/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571809
Principal investigator 1 Genentech, Inc. $152.00 08/06/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571805
Principal investigator 1 GENZYME CORPORATION $800.00 08/04/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088568
Principal investigator 1 Celgene Corporation $6,755.00 06/25/2025 Non-covered Recipient Entity
Parkview Physicians Group Neurology
A Multicenter, Longitudinal, Open-Label, Single-Arm Study Describing Cognitive Processing Speed Changes in Relapsing Multiple Sclerosis Subjects Treated with Ozanimod (RPC-1063) No dispute reported 06/30/2026 1222306192
Principal investigator 1 GENZYME CORPORATION $4,500.00 06/16/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088562
Principal investigator 1 GENZYME CORPORATION $4,000.00 05/27/2025 Non-covered Recipient Entity
Iu Health Neurology Fort Wayne
A Phase 3, Randomized, Double-blind Efficacy and Safety Study Comparing SAR442168 to Teriflunomide (Aubagio) in Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226091685
Principal investigator 1 Novartis Pharmaceuticals Corporation $143,341.24 05/08/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304111
Principal investigator 1 Genentech, Inc. $180.00 04/16/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571802
Principal investigator 1 GENZYME CORPORATION $20,850.00 03/10/2025 Non-covered Recipient Entity
Indiana University Health Inc Attn Char Schaffer
Master Protocol of Two Independent, Randomized, Double-blind, Phase 3 Studies Comparing Efficacy and Safety of Frexalimab (SAR441344) to Teriflunomide in Adult Participants With Relapsing Forms of Multiple Sclerosis No dispute reported 06/30/2026 1226088556
Principal investigator 1 Genentech, Inc. $2,876.00 01/22/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571789
Principal investigator 1 GENZYME CORPORATION $9,510.60 01/21/2025 Non-covered Recipient Entity
Indiana University Health Inc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092113
Principal investigator 1 GENZYME CORPORATION $13,600.00 01/21/2025 Non-covered Recipient Entity
Indiana University Health Inc
An Interventional, Phase 3 Extension Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Relapsing Multiple Sclerosis, Primary Progressive Multiple Sclerosis, or Nonrelapsing Secondary Progressive Multiple Sclerosis No dispute reported 06/30/2026 1226092119
Principal investigator 1 Genentech, Inc. $179.00 01/14/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571793
Principal investigator 1 Genentech, Inc. $86.00 01/13/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571784
Principal investigator 1 Genentech, Inc. $179.00 01/13/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC FORT WAYNE NEUROLOGICAL CTR
Evaluation of Fenebrutinib in RMS patients No dispute reported 06/30/2026 1211571797
Principal investigator 1 Novartis Pharmaceuticals Corporation $184,575.95 01/07/2025 Non-covered Recipient Entity
ALLIED PHYSICIANS INC
A Randomized, Double-blind, Double-dummy, Parallel-group Study, Comparing the Efficacy and Safety of Remibrutinib Versus Teriflunomide in Participants With Relapsing Multiple Sclerosis, Followed by Extended Treatment With Open-label Remibrutinib No dispute reported 06/30/2026 1190304109